Ductal Adenocarcinoma of the Pancreas
Conditions
Keywords
Ductal Adenocarcinoma, Pancreatectomies, Whipple
Brief summary
Recently, more and more total pancreatectomy (TP) has been performed for pancreatic ductal cell adenocarcinoma (PDCA) which abuts or involves both gastroduodenal and splenic arteries. Warshaw's procedure (spleen-preserving distal pancreatectomy with excision of splenic vessels) has been safely performed for years. Likewise, both pancreatic tail and spleen can be preserved after excision of splenic vessels for leftward extension of pancreatic parenchyma transaction line during Whipple (WOTSA). In that case, TP can be replaced by WOTSA. This uncontrolled before and after study assesses the safety and efficacy of a new technique Whipple over the splenic artery (WOTSA) as a treatment for PDAC which traditionally requires total pancreatectomy (TP).
Detailed description
Recently, more and more total pancreatectomy (TP) has been performed for pancreatic ductal cell adenocarcinoma (PDCA) which abuts or involves both gastroduodenal and splenic arteries. Warshaw's procedure (spleen-preserving distal pancreatectomy with excision of splenic vessels) has been safely performed for years. Likewise, both pancreatic tail and spleen can be preserved after excision of splenic vessels for leftward extension of pancreatic parenchyma transaction line during Whipple (WOTSA). In that case, TP can be replaced by WOTSA. This uncontrolled before and after study assesses the safety and efficacy of a new technique Whipple over the splenic artery (WOTSA) as a treatment for PDAC which traditionally requires total pancreatectomy (TP). Methods: The study group comprised 40 consecutive patients who underwent WOTSA for PDAC. Their clinicopathological characteristics and survival were compared with those of a historical control group comprising 30 consecutive patients who underwent TP between.
Interventions
Treatment for pancreatic ductal cell adenocarcinoma
Treatment for pancreatic ductal cell adenocarcinoma
Sponsors
Study design
Eligibility
Inclusion criteria
* pancreatic ductal cell adenocarcinoma (PDCA) patients
Exclusion criteria
* Patient undergoing palliative pancreatectomy, other malignancies with distant metastases * Vulnerable groups
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinicopathological characteristics | before | Measurement of the remnant pancreatic volume |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative chemotherapy and follow-up | 1 month after the operation | Measurement of the remnant pancreatic volume and physiological parameters |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | 1 day before the operation | Measurement of the physiological parameters |
Countries
Taiwan